SCORE
发表于 2025-3-30 08:20:50
http://reply.papertrans.cn/19/1873/187291/187291_51.png
Allergic
发表于 2025-3-30 15:59:41
nd biologic agents, as well as their clinical efficacy and s. .Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agen
Amenable
发表于 2025-3-30 20:18:05
Von der Nachkriegsnot zur Familienpolitik,logics. The chapter also discusses biosimilars and the complexity of their development and manufacturing along with highlighting the differences between two often-confused terms—biosimilarity and comparability.
迷住
发表于 2025-3-30 22:36:01
Manufacturing of Biologics,logics. The chapter also discusses biosimilars and the complexity of their development and manufacturing along with highlighting the differences between two often-confused terms—biosimilarity and comparability.
Geyser
发表于 2025-3-31 01:47:10
http://reply.papertrans.cn/19/1873/187291/187291_55.png
Biguanides
发表于 2025-3-31 08:56:48
http://reply.papertrans.cn/19/1873/187291/187291_56.png
表示问
发表于 2025-3-31 10:33:38
Interpreting Clinical Trial Data,nical trials directly impacts clinical decision making, which ultimately guides patient management (Page, Int J Sports Phys Ther 9: 726, 2014). The purpose of this chapter is to provide an overview of fundamental aspects of clinical trials, such as study designs, analyses, and methods of handling mi
护航舰
发表于 2025-3-31 14:48:29
http://reply.papertrans.cn/19/1873/187291/187291_58.png
Embolic-Stroke
发表于 2025-3-31 19:08:32
Quality of Life in the Dermatology Practice,ical functioning. The impact of these diseases on quality of life (QOL) can be significant, and the psychosocial impact of many dermatologic diseases is often more impactful than the physical appearance or symptoms alone. We now know that many chronic dermatologic conditions are more than skin deep,
古董
发表于 2025-4-1 01:34:57
Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis,n reported and the warning labels have expanded. A variety of issues are now linked to biologic associated tumor necrosis factor-alpha (TNF-α) blocker use. Litigation has occurred with the use of a variety of biologics. The published risks of these agents include the development of lupus and autoimm